BAY-1797 (12.5-50 mg/kg; pO.) significantly increases PGE2 levels in the inflamed paw within the mouse Complete Freund’s Adjuvant (CFA) inflammatory pain model^[1].

BAY-1797 (50 mg/kg; once daily for multiple pO. administrations) significantly lowers the load on the ipsilateral paw 24 and 48 hours post Complete Freund’s Adjuvant (CFA) injection^[1].

Under BAY-1797 treatment, the normalized area under the curve (AUCnorm), steady-state volume of distribution (Vss), and half-life (t1/2) are reported as 1.06 kg h/L, 3.67 L/kg, and 2.64 hours, respectively^[1].

BAY-1797 blocks P2X4 in 1321N1 cells across human, mouse, and rat species, showing IC50 values of 108 nM, 112 nM, and 233 nM, respectively^[1].

BAY-1797 shows no significant activity against hERG and carbonic anhydrase II (both IC50 >10 μM). Additionally, when assessed against a variety of non-target entities such as G-protein coupled receptors (GPCRs), ion channels, kinases, and transporters at 10 μM, the only observed inhibitory effect was on the dopamine transporter (DAT, with an IC50 of 2.17 μM)^[1].